; and (VIII) other best practices, such as prevention of addiction, as identified by the Secretary, after consultation with practitioners from a variety of medical specialties and who practice in different settings in which controlled substances are prescribed. (v) The physician has participated as an investigator in one or more clinical trials leading to the approval of a narcotic drug in schedule III, IV, or V for maintenance or detoxification treatment, as demonstrated by a statement submitted to the Secretary by the sponsor of such approved drug. (vi) The physician has such other training or experience as the State medical licensing board of the State where the physician will provide maintenance or detoxification treatment considers to demonstrate the ability of the physician to treat and manage patients with opioid and other substance use disorders. (vii) The physician has such other training or experience as the Secretary considers to demonstrate the ability of the physician to treat and manage patients with opioid and other substance use disorders. Any criteria of the Secretary under this clause shall be established by regulation. Any such criteria are effective only for 3 years after the date on which the criteria are promulgated, but may be extended for such additional discrete 3-year periods as the Secretary considers appropriate for purposes of this clause. Such an extension of criteria may only be effectuated through a statement published in the Federal Register by the Secretary during the 30-day period preceding the end of the 3-year period involved. (viii) The physician graduated in good standing from an accredited school of allopathic medicine or osteopathic medicine in the United States during the 5-year period immediately preceding the date on which the physician first registers or renews under this section and has successfully completed a comprehensive allopathic or osteopathic medicine curriculum or accredited medical residency that— (I) included not less than 8 hours of training on treating